Study of oral cladribine for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an oral form of cladribine, a chemotherapy drug, for people with acute myeloid leukemia (AML). It includes two parts: one for AML that has come back or not responded to treatment, and another for newly diagnosed AML in certain older adults or those with specific genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AML that has returned or not improved after treatment, or be newly diagnosed with certain types of AML (like therapy-related AML, monocytic AML, or AML with RAS mutations)
- If you are newly diagnosed and over 60, you may qualify if you have a specific AML subtype or genetic mutation
- Your kidneys and liver must be working well enough (based on blood tests)
- Your heart function must be normal (measured with an echocardiogram)
- You must be able to swallow oral capsules without altering them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.